Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637130 · ClinicalTrials.gov registry record · Phase 2
Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00637130 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 138 participants.
The verdict
NCT00637130, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
Interventions
- OTHER Vehicle
- DRUG Travoprost ophthalmic solution, 0.0008%
- DRUG Travoprost ophthalmic solution, 0.001%
- DRUG Travoprost ophthalmic solution, 0.0012%
- DRUG TRAVATAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637130
The ClinicalTrials.gov registry entry for NCT00637130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vehicle is the first listed.
NCT00637130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637130 about?
NCT00637130 is a clinical study titled "Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost". The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00637130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2007-10.
What interventions are being tested in trial NCT00637130?
The interventions under investigation include: Vehicle (OTHER), Travoprost ophthalmic solution, 0.0008% (DRUG), Travoprost ophthalmic solution, 0.001% (DRUG), Travoprost ophthalmic solution, 0.0012% (DRUG), TRAVATAN (DRUG).
Who is sponsoring clinical trial NCT00637130?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.